Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
about
CAR T Cell Therapy: A Game Changer in Cancer TreatmentGene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Chimeric antigen receptor T cells: a novel therapy for solid tumors.The growing world of CAR T cell trials: a systematic review.Tumor-targeting domains for chimeric antigen receptor T cells.Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment conceptsIncorporation of functional elements enhances the antitumor capacity of CAR T cells.Clinical trials of CAR-T cells in ChinaInterleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.Cancer immunotherapy: A need for peripheral immunodynamic monitoring.Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.CAR-T cells: the long and winding road to solid tumors.Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.The application of CAR-T cell therapy in hematological malignancies: advantages and challengesImproving Immunotherapy Through Glycodesign
P2860
Q26822769-F9694FAA-E80A-4CCE-AB82-86CD1E83A484Q33913839-4B855F56-1C73-43DF-A83E-C33138A88EEEQ34553167-CE8FD828-E70D-4861-A74B-EB1811F9A2B2Q37728639-4926E4A2-3B70-4565-B511-3C1B124B0A57Q38950791-12BC4A3B-E255-4894-BDE2-1EE6CF98E799Q39045535-3F498605-E03B-43B3-9FE8-BBBEAE64BCF7Q41600980-C17AD2AB-DE77-4688-93EB-5055D72826CBQ42375194-6C52DEC1-F103-4F67-AF5A-C368C2CB4F76Q42654456-04BE85E0-9A3D-48C0-88E6-4ED0CFFF2A73Q45870945-6A6FD34C-ADEC-44F4-91B6-C392F4E50438Q47561904-68837E9A-85D1-466D-8761-AC202F251C2BQ47629566-160EBA37-AF06-4C3E-9AF2-1D28140C8EA0Q49280922-2992B320-FED6-4792-B8D8-7331DD233170Q49722635-06AB8A48-7B89-4854-BC60-8B451328F3DAQ49959264-62A003E0-C13F-47B4-87C4-3E03AF6804F0Q54979818-25A52EC4-57F2-4D1D-BF9B-4FD99D823F71Q55382852-69B13105-2B9E-426F-A1CA-FCF588BC7D1AQ57177485-61BDFE78-9036-46C2-9FF7-4F4F6EB3BE1BQ59132146-1025BDC1-715F-46A0-93DC-70141E7A7AAC
P2860
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Phase 1 clinical trial demonst ...... n receptor transduced T cells.
@en
type
label
Phase 1 clinical trial demonst ...... n receptor transduced T cells.
@en
prefLabel
Phase 1 clinical trial demonst ...... n receptor transduced T cells.
@en
P2093
P2860
P1476
Phase 1 clinical trial demonst ...... n receptor transduced T cells.
@en
P2093
Bozhen Zhang
Fengtao You
Huimin Meng
Jirong Tang
Licui Jiang
P2860
P2888
P304
P356
10.1007/S11427-016-5024-7
P577
2016-03-07T00:00:00Z
P5875
P6179
1003709511